ATE337312T1 - Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen - Google Patents
Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasenInfo
- Publication number
- ATE337312T1 ATE337312T1 AT02744355T AT02744355T ATE337312T1 AT E337312 T1 ATE337312 T1 AT E337312T1 AT 02744355 T AT02744355 T AT 02744355T AT 02744355 T AT02744355 T AT 02744355T AT E337312 T1 ATE337312 T1 AT E337312T1
- Authority
- AT
- Austria
- Prior art keywords
- inhibitors
- src
- pyrimidines
- isoxazolyl
- protein kinases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30296901P | 2001-07-03 | 2001-07-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE337312T1 true ATE337312T1 (de) | 2006-09-15 |
Family
ID=23170022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02744355T ATE337312T1 (de) | 2001-07-03 | 2002-06-14 | Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen |
Country Status (9)
Country | Link |
---|---|
US (2) | US6689778B2 (de) |
EP (1) | EP1417205B1 (de) |
JP (1) | JP4342937B2 (de) |
AT (1) | ATE337312T1 (de) |
CA (1) | CA2452603A1 (de) |
DE (1) | DE60214198T2 (de) |
ES (1) | ES2271283T3 (de) |
HK (1) | HK1065540A1 (de) |
WO (1) | WO2003004492A1 (de) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
CA2422377C (en) | 2000-09-15 | 2010-04-13 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7473691B2 (en) * | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
EP1345922B1 (de) * | 2000-12-21 | 2006-05-31 | Vertex Pharmaceuticals Incorporated | Pyrazolverbindungen als protein-kinase-inhibitoren |
CA2452603A1 (en) * | 2001-07-03 | 2003-01-16 | Vertex Pharmaceuticals Incorporated | Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
ES2437391T3 (es) * | 2002-02-06 | 2014-01-10 | Vertex Pharmaceuticals, Inc. | Compuestos de heteroarilo útiles como inhibidores de GSK-3 |
ATE468336T1 (de) * | 2002-03-15 | 2010-06-15 | Vertex Pharma | Azolylaminoazine als proteinkinasehemmer |
MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
KR20050032105A (ko) | 2002-08-02 | 2005-04-06 | 버텍스 파마슈티칼스 인코포레이티드 | Gsk-3의 억제제로서 유용한 피라졸 조성물 |
EP1546141A1 (de) * | 2002-09-06 | 2005-06-29 | Vertex Pharmaceuticals Incorporated | Isoxazole und deren verwendung in der behandlung ischämischer krankheiten |
KR20110050745A (ko) * | 2002-10-03 | 2011-05-16 | 탈자진 인코포레이티드 | 혈관항상성 유지제 및 그의 사용 방법 |
US20050282814A1 (en) * | 2002-10-03 | 2005-12-22 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
WO2004072029A2 (en) * | 2003-02-06 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridazines useful as inhibitors of protein kinases |
US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
US7442698B2 (en) | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
AR045595A1 (es) * | 2003-09-04 | 2005-11-02 | Vertex Pharma | Composiciones utiles como inhibidores de proteinas quinasas |
JP2007513184A (ja) * | 2003-12-04 | 2007-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なキノキサリン |
WO2005080392A1 (ja) | 2004-02-19 | 2005-09-01 | Takeda Pharmaceutical Company Limited | ピラゾロキノロン誘導体およびその用途 |
NZ551027A (en) * | 2004-04-08 | 2011-01-28 | Targegen Inc | Benzotriazine inhibitors of kinases |
AU2005276974B2 (en) | 2004-08-25 | 2012-08-02 | Targegen, Inc. | Heterocyclic compounds and methods of use |
WO2006070927A1 (ja) | 2004-12-28 | 2006-07-06 | Aska Pharmaceutical Co., Ltd. | ピリミジニルイソオキサゾール誘導体 |
NZ563984A (en) * | 2005-06-08 | 2011-11-25 | Targegen Inc | Methods and compositions for the treatment of ocular disorders |
WO2007022384A2 (en) * | 2005-08-18 | 2007-02-22 | Vertex Pharmaceuticals Incorporated | Pyrazine kinase inhibitors |
US8133900B2 (en) * | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
EP1951684B1 (de) * | 2005-11-01 | 2016-07-13 | TargeGen, Inc. | Biarylmetapyrimidinkinaseinhibitoren |
CN103145702A (zh) * | 2005-11-03 | 2013-06-12 | 顶点医药品公司 | 用作激酶抑制剂的氨基嘧啶 |
WO2007127366A2 (en) * | 2006-04-25 | 2007-11-08 | Targegen, Inc. | Kinase inhibitors and methods of use thereof |
NZ576750A (en) * | 2006-11-02 | 2012-01-12 | Vertex Pharma | Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases |
DE602007007985D1 (de) * | 2006-12-19 | 2010-09-02 | Vertex Pharma | Als inhibitoren von proteinkinasen geeignete aminopyrimidine |
WO2008112642A1 (en) * | 2007-03-09 | 2008-09-18 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
CA2680029A1 (en) * | 2007-03-09 | 2008-09-18 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
AU2008226461A1 (en) * | 2007-03-09 | 2008-09-18 | Vertex Pharmaceuticals Incorporated | Aminopyridines useful as inhibitors of protein kinases |
AU2008240313A1 (en) | 2007-04-13 | 2008-10-23 | Aj Park | Aminopyrimidines useful as kinase inhibitors |
CN101679387A (zh) * | 2007-05-02 | 2010-03-24 | 沃泰克斯药物股份有限公司 | 可用作激酶抑制剂的氨基嘧啶类化合物 |
CN101801959A (zh) * | 2007-05-02 | 2010-08-11 | 沃泰克斯药物股份有限公司 | 可用作激酶抑制剂的氨基嘧啶类化合物 |
EP2152694A2 (de) | 2007-05-02 | 2010-02-17 | Vertex Pharmaceuticals Incorporated | Als kinaseinhibitoren geeignete thiazole und pyrazole |
AU2008257044A1 (en) * | 2007-05-24 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
WO2009018415A1 (en) * | 2007-07-31 | 2009-02-05 | Vertex Pharmaceuticals Incorporated | Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof |
TW200911761A (en) | 2007-08-29 | 2009-03-16 | Boehringer Ingelheim Int | New B1-antagonists |
AU2009214440B2 (en) | 2008-02-15 | 2014-09-25 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases |
MX2011002312A (es) * | 2008-09-03 | 2011-04-26 | Vertex Pharma | Co-cristales y formulaciones farmaceuticas que comprenden los mismos. |
EP2401256B1 (de) * | 2009-02-26 | 2013-04-17 | Boehringer Ingelheim International GmbH | Verbindungen als Bradykinin-B1-Antagonisten |
AU2010363329A1 (en) | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
SI3459942T1 (sl) | 2012-04-24 | 2021-05-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
EA035349B1 (ru) | 2012-11-21 | 2020-05-29 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | ЗАМЕЩЕННЫЕ ПИРИМИДИНОВЫЕ ОБРАТНЫЕ ИНГИБИТОРЫ Bmi-1 |
CN107200749B (zh) | 2013-03-12 | 2019-09-03 | 沃泰克斯药物股份有限公司 | Dna-pk抑制剂 |
TWI692477B (zh) * | 2013-08-30 | 2020-05-01 | 美商Ptc治療公司 | 經取代嘧啶bmi-1抑制劑 |
RS60426B1 (sr) | 2013-10-17 | 2020-07-31 | Vertex Pharma | Kokristali (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)hinolin-4-karboksamida i njihovi deuterisani derivati kao inhibitori dnk-pk |
EP3071553A4 (de) | 2013-11-21 | 2017-08-02 | PTC Therapeutics, Inc. | Substituierte pyridin- und pyrazin-bmi-1-hemmer |
EP3194572B1 (de) | 2014-07-30 | 2023-10-25 | Yeda Research and Development Co. Ltd. | Medien zur kultivierung pluripotenter stammzellen |
US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
SG10202102920QA (en) * | 2016-05-26 | 2021-05-28 | Recurium Ip Holdings Llc | Egfr inhibitor compounds |
CA3038657A1 (en) | 2016-09-27 | 2018-04-05 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors |
WO2019155468A1 (en) * | 2018-02-08 | 2019-08-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use |
WO2020152686A1 (en) | 2019-01-23 | 2020-07-30 | Yeda Research And Development Co. Ltd. | Culture media for pluripotent stem cells |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020030791A (ko) * | 1999-08-12 | 2002-04-25 | 버텍스 파마슈티칼스 인코포레이티드 | c-JUN N-말단 키나제(JNK) 및 기타의 단백질키나제 억제제 |
JP2005500261A (ja) * | 2001-04-10 | 2005-01-06 | バーテックス ファーマシューティカルズ インコーポレイテッド | Srcおよび他のプロテインキナーゼのインヒビターとしてのイソキサゾール誘導体 |
CA2452603A1 (en) * | 2001-07-03 | 2003-01-16 | Vertex Pharmaceuticals Incorporated | Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
-
2002
- 2002-06-14 CA CA002452603A patent/CA2452603A1/en not_active Abandoned
- 2002-06-14 DE DE60214198T patent/DE60214198T2/de not_active Expired - Lifetime
- 2002-06-14 EP EP02744355A patent/EP1417205B1/de not_active Expired - Lifetime
- 2002-06-14 WO PCT/US2002/018956 patent/WO2003004492A1/en active IP Right Grant
- 2002-06-14 US US10/171,895 patent/US6689778B2/en not_active Expired - Fee Related
- 2002-06-14 AT AT02744355T patent/ATE337312T1/de not_active IP Right Cessation
- 2002-06-14 JP JP2003510659A patent/JP4342937B2/ja not_active Expired - Fee Related
- 2002-06-14 ES ES02744355T patent/ES2271283T3/es not_active Expired - Lifetime
-
2003
- 2003-12-04 US US10/728,113 patent/US20050049246A1/en not_active Abandoned
-
2004
- 2004-10-25 HK HK04108356A patent/HK1065540A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE60214198D1 (de) | 2006-10-05 |
EP1417205B1 (de) | 2006-08-23 |
HK1065540A1 (en) | 2005-02-25 |
WO2003004492A1 (en) | 2003-01-16 |
US6689778B2 (en) | 2004-02-10 |
JP4342937B2 (ja) | 2009-10-14 |
US20050049246A1 (en) | 2005-03-03 |
JP2004536114A (ja) | 2004-12-02 |
EP1417205A1 (de) | 2004-05-12 |
US20030171389A1 (en) | 2003-09-11 |
CA2452603A1 (en) | 2003-01-16 |
DE60214198T2 (de) | 2007-08-09 |
ES2271283T3 (es) | 2007-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE337312T1 (de) | Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen | |
DE60316013D1 (de) | Heteroaryl-pyrimidinderivate als jak-inhibitoren | |
NO20053470L (no) | Triazolopyridaziner som proteinkinase-inhibitorer | |
WO2002085909A8 (en) | 9-deazaguanine derivatives as inhibitors of gsk-3 | |
DE60214703D1 (de) | Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen | |
MXPA03010961A (es) | Compuestos de tiazol utiles como inhibidores de proteinas cinasas. | |
DE60332433D1 (de) | Azolylaminoazine als proteinkinasehemmer | |
DE60332604D1 (de) | Azolylaminoazine als proteinkinasehemmer | |
DE60314603D1 (de) | Zusammensetzungen brauchbar als protein-kinase- inhibitoren | |
MY141739A (en) | Substituted quinazoline derivatives as inhibitors of aurora kinases | |
ATE432929T1 (de) | 5-(2-aminopyrimidin-4-yl)benzisoxazole als proteinkinasehemmer | |
NO20070526L (no) | Kinazolindionderivater som parp-inhibitorer | |
ATE466581T1 (de) | Verbindungen auf pyrimidin-basis als gsk-3-hemmer | |
ATE536353T1 (de) | 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren | |
DE60330895D1 (de) | Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen | |
WO2002083667A3 (en) | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases | |
ATE469888T1 (de) | Indazol-, benzisoxazol- und benzisothiazol- kinaseinhibitoren | |
NO20070557L (no) | Ftalazinderivater som PARP-inhibitorer | |
DE60327999D1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
GEP20053600B (en) | 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors | |
BR0308243A (pt) | Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero | |
AU2003297160A1 (en) | Benzisoxazole derivatives useful as inhibitors of protein kinases | |
BR0313176A (pt) | Composições de pirazol úteis como inibidores de gsk-3 | |
ATE359791T1 (de) | Pyrimidin-2,4-dion-derivate als matrix- metalloproteinase-hemmer | |
DE60108626D1 (de) | Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |